Valuation: Personalis, Inc.

Market Cap 1.23B 1.08B 1.01B 925M 1.74B 119B 1.76B 11.97B 4.67B 58.41B 4.63B 4.53B 202B P/E 2026 *
-11.5x
P/E 2027 * -13x
Enterprise Value 1.06B 927M 863M 792M 1.49B 102B 1.51B 10.24B 4B 50B 3.96B 3.88B 173B EV / Sales 2026 *
13.4x
EV / Sales 2027 * 10.5x
Free-Float
73.84%
Yield 2026 *
-
Yield 2027 * -
1 day-3.60%
1 week-23.46%
Current month-12.09%
1 month+3.70%
3 months+93.11%
6 months+15.83%
Current year+47.99%
1 week 11.74
Extreme 11.735
14.75
1 month 11.74
Extreme 11.735
16.39
Current year 4.96
Extreme 4.955
16.39
1 year 3.84
Extreme 3.84
16.39
3 years 0.89
Extreme 0.8906
16.39
5 years 0.89
Extreme 0.8906
23.04
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 01/03/2023
Chief Executive Officer 65 30/12/2022
President 55 12/03/2026
Director TitleAgeSince
Director/Board Member 79 30/04/2019
Chairman 76 16/05/2022
Director/Board Member 72 05/03/2021
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Fiscal year

Chairperson

300,000 0.2865%
09/07/26 Fiscal year

Chief Executive Officer

300,000 0.2865%
29/06/26 Fiscal year

Chief Financial Officer

14,946 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
-3.60%-23.46%+75.56%+445.37% 1.23B
+1.07%-3.49%-3.25%+12.87% 46.86B
+0.25%+1.65%+408.41%+629.49% 40.23B
-0.27%+4.45%+9.93%+66.92% 36.23B
+0.35%+0.87%+3.60%-8.81% 34.72B
+3.14%+1.02%+3.37%+38.15% 27.89B
-0.73%+11.84%+31.97%+143.53% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%+0.76%+8.50% 13.12B
-2.68%-2.49%-15.00%-31.68% 12.7B
Average -0.16%-1.60%+57.26%+144.93% 24.65B
Weighted average by Cap. +0.46%+0.79%+75.32%+138.30%

Financials

2026 *2027 *
Net sales 78.77M 69.19M 64.34M 59.04M 111M 7.59B 113M 764M 299M 3.73B 296M 289M 12.89B 109M 96.01M 89.29M 81.93M 154M 10.53B 156M 1.06B 414M 5.18B 410M 402M 17.89B
Net income -108M -94.77M -88.13M -80.87M -152M -10.39B -154M -1.05B -409M -5.11B -405M -396M -17.66B -95.61M -83.97M -78.09M -71.66M -135M -9.21B -137M -927M -362M -4.53B -359M -351M -15.65B
Net Debt -178M -156M -145M -133M -250M -17.1B -254M -1.72B -673M -8.41B -667M -652M -29.07B -91.04M -79.96M -74.36M -68.24M -128M -8.77B -130M -883M -345M -4.31B -342M -334M -14.9B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
24/07/26 US$11.78 -3.60% 2,900,374
23/07/26 US$12.22 -2.00% 3,745,715
22/07/26 US$12.47 -7.22% 4,044,991
21/07/26 US$13.44 +0.75% 6,812,302
20/07/26 US$13.34 -13.32% 12,072,446
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
11.78USD
Average target price
13.88USD
Spread / Average Target
+17.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock